for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Athenex Inc

ATNX.OQ

Latest Trade

17.75USD

Change

1.31(+7.97%)

Volume

322,592

Today's Range

16.50

 - 

17.80

52 Week Range

8.87

 - 

21.11

As of on the NASDAQ ∙ Minimum 15 minute delay

Pricing

Previous Close
16.44
Open
16.66
Volume
322,592
3M AVG Volume
21.77
Today's High
17.80
Today's Low
16.50
52 Week High
21.11
52 Week Low
8.87
Shares Out (MIL)
77.47
Market Cap (MIL)
1,375.73
Forward P/E
-9.36
Dividend (Yield %)
--

Latest Developments

More

Athenex Announces $60 Million Private Placement

Athenex, Inc. Announces Third Quarter 2019 Financial Results

Athenex Says Recent Shortseller Reports Contain "Inaccurate Information"

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Athenex Inc

Athenex, Inc. is an oncology pharmaceutical company focused on the development and commercialization of therapies for cancer diseases and supportive therapies. The Company's technology platform is organized into three categories, including Oral Absorption Platform, Src Kinase Inhibitors and Symptom Therapeutics. The Company offers Oraxol, an oral formulation of paclitaxel; Orateacan, an oral formulation of Irinotecan; Oradoxel, an oral formulation of Docetaxel, and an oral formulation of Topotecan for the treatment of various types of cancers. Its Src Kinase Inhibitors include KX-01 (KX2-391) and KX-02 (KX2-361) oncology drug candidates. The Company's Symptom Therapeutics include CQ-01, which is used for the treatment of burn pruritus and scars; CQ-R1, which is used for the treatment of an irradiation-induced dermatitis, and an intranasal Granisetron used for the treatment of chemotherapy-induced nausea/vomiting.

Industry

Biotechnology & Drugs

Contact Info

1001 Main St Ste 600

+1.716.8988625

https://www.athenex.com/

Executive Leadership

Johnson Y.N. Lau

Chief Executive Officer and Chairman of the Board

Randoll Sze

Chief Financial Officer

Daniel Lang

President of Axis Therapeutics Limited and Senior Director of Corporate Development

William W. Zuo

President, Polymed Therapeutic

Jeffrey M. Yordon

Chief Operating Officer and President, Athenex Pharmaceutical Division

Key Stats

1.75 mean rating - 8 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2017

0.0K

2018

0.1K

2019(E)

0.1K
EPS (USD)

2017

-2.630

2018

-1.820

2019(E)

-1.756
Price To Earnings (TTM)
--
Price To Sales (TTM)
15.61
Price To Book (MRQ)
9.39
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
36.61
LT Debt To Equity (MRQ)
35.96
Return on Investment (TTM)
-61.71
Return on Equity (TTM)
-48.97

Latest News

Latest News

BRIEF-Athenex Meets Enrollment Target For Late Stage Breast Cancer Trial

* ATHENEX MEETS ENROLLMENT TARGET FOR ORAXOL PHASE III CLINICAL TRIAL IN METASTATIC BREAST CANCER

BRIEF-Athenex Says Patient Enrollment For Two Late Stage Studies Of Actinic Keratosis Treatment Completed

* ATHENEX ANNOUNCES EARLY COMPLETION OF PATIENTS ENROLLMENT FOR TWO PHASE III CLINICAL STUDIES OF KX2-391 OINTMENT FOR ACTINIC KERATOSIS Source text for Eikon: Further company coverage:

BRIEF-Athenex Announces Pricing Of Offering Of Common Stock

* ATHENEX, INC. ANNOUNCES PRICING OF OFFERING OF COMMON STOCK

BRIEF-Athenex Announces Proposed Offering Of Common Stock

* SAYS OFFERING 4.30 MILLION COMMON SHARES Source text for Eikon: Further company coverage:

BRIEF-Athenex Announces Encouraging Early Clinical Efficacy And Safety Data Of Oraxol

* ATHENEX ANNOUNCES ENCOURAGING EARLY CLINICAL EFFICACY AND SAFETY DATA OF ORAXOL IN CLINICAL TRIAL FOR THE TREATMENT OF BREAST CANCER

BRIEF-Athenex Files For Offering Of Up To 4.3 Million Shares

* ATHENEX INC FILES FOR OFFERING OF UP TO 4.3 MILLION SHARES - SEC FILING Source text : (http://bit.ly/2Dr3FzB) Further company coverage:

BRIEF-Athenex Announces`Results Of First Cohort Of Phase I Clinical Trial Of Gastric Cancer Treatment

* ATHENEX ANNOUNCES ENCOURAGING RESULTS OF THE FIRST COHORT OF PHASE I CLINICAL TRIAL OF ORAXOL AND CYRAMZA® (RAMUCIRUMAB) COMBINATION TREATMENT IN GASTRIC CANCER Source text for Eikon: Further company coverage: (Bengaluru Newsroom: +1 646 223 8780)

BRIEF-Athenex Receives Positive Feedback From FDA On The Design Of Phase III Clinical Trial For Oraxol

* ATHENEX RECEIVES POSITIVE FEEDBACK FROM FDA ON THE DESIGN OF PHASE III CLINICAL TRIAL FOR ORAXOL

BRIEF-Athenex Announces Chinese FDA Allowance Of Investigational New Drug Application Of Oraxol To Begin Clinical Trials

* ATHENEX ANNOUNCES CHINESE FDA ALLOWANCE OF INVESTIGATIONAL NEW DRUG APPLICATION OF ORAXOL TO BEGIN CLINICAL TRIALS

BRIEF-Athenex Receives Promising Innovative Medicine Designation From The UK MHRA For Oraxol

* ATHENEX RECEIVES PROMISING INNOVATIVE MEDICINE DESIGNATION FROM THE UNITED KINGDOM MHRA FOR ORAXOL, AN INNOVATIVE ORAL FORM OF PACLITAXEL Source text for Eikon: Further company coverage:

BRIEF-Athenex Inc ‍Initiates Oral Eribulin Investigational New Drug Development Program For Oncology Indications​

* ATHENEX INC - INITIATION OF AN ORAL ERIBULIN INVESTIGATIONAL NEW DRUG DEVELOPMENT PROGRAM FOR ONCOLOGY INDICATIONS Source text for Eikon: Further company coverage:

BRIEF-Almirall And Athenex Announces Partnership For Treatment Of Actinic Keratosis

* ALMIRALL AND ATHENEX ANNOUNCE STRATEGIC PARTNERSHIP FOR THE TREATMENT OF ACTINIC KERATOSIS

BRIEF-Athenex Announces Planned Retirement Of Chief Financial Officer Nick Riehle

* ATHENEX ANNOUNCES PLANNED RETIREMENT OF CHIEF FINANCIAL OFFICER NICK RIEHLE

BRIEF-Athenex announces Q3 revenue of $14 million

* Says company raises full-year revenue guidance to range of $33 million - $35 million

BRIEF-Athenex announces positive recommendations from the ‍DSMB to continue the oraxol phase iii program

* Athenex announces positive recommendations from the Drug Safety Monitoring Board to continue the oraxol phase iii program

BRIEF-Athenex Inc announces first patient recruitment in phase III clinical trials for KX-01 ointment

* Athenex, Inc. announces first patient recruitment in phase III clinical trials for KX-01 ointment for actinic keratosis

BRIEF-Athenex Inc announces second quarter 2017 results

* Athenex Inc - expect full-year revenues in range of $30 million to $34 million, inclusive of opportunity created by U.S. sodium bicarbonate shortage Source text for Eikon: Further company coverage:

BRIEF-Athenex announces approval of tax incentives from State of New York for Dunkirk facility

* Athenex inc - obtained new york state and local tax incentives related to its pharmaceutical manufacturing facility in town of dunkirk, new york

BRIEF-Athenex reports commencement of patient enrollment for oraxol-plus-ramucirumab phase 1b clinical trial in gastric cancer

* Athenex Inc. announces commencement of patient enrollment for oraxol-plus-ramucirumab phase 1b clinical trial in gastric cancer Source text for Eikon: Further company coverage:

BRIEF-Huateng Ma reports 11.6 pct passive stake in Athenex

* Huateng Ma reports 11.6 percent passive stake in Athenex Inc as of June 14 - SEC filing Source: (http://bit.ly/2ueJu6F) Further company coverage:

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up